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To determine the factors associated with gait parameters in female patients with rheumatoid
arthritis (RA).
Methods
The gait analysis was performed in a large cohort of RA patients, and three basic gait
parameters (step length, cadence and gait speed) were calculated. Clinical and laboratory
data were also collected. Factors associated with gait parameters were analyzed using mul-
tivariable linear regression in the three models with forced entry. Then, we divided those
patients with Health Assessment Questionnaire disability index (HAQ) scores 0.5 into two
groups according to their gait speed that were compared to identify the characteristics of
patients with a good HAQ score but poor walking ability.
Results
A total of 318 female patients were analyzed. Knee extension strength had the strongest
positive association with all three gait parameters (P < 0.0001), while methotrexate use was
also positively associated with all three gait parameters (step length: P < 0.05, cadence: P <
0.05 in model 1 and 2; P < 0.01 in model 3, gait speed: P < 0.01). The disease activity score
was negatively associated with step length and gait speed (step length, gait speed: P < 0.01
in model 1 and 2; P < 0.05 in model 3). 26% of patients with good HAQ scores showed slow
gait speed. Patients with good HAQ scores and slow gait speed had higher disease activity
scores (P < 0.05) and lower knee extension strength (P < 0.0001) than those with good
HAQ scores and normal gait speed.
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Conclusions
High knee extension strength, low disease activity and administration of methotrexate were
strongly associated with good walking ability in female patients with RA. And, even if
patients showed good HAQ scores, about quarter of those patients had poor walking ability,
and they showed higher disease activity, lower knee extension strength, compared to the
patients with normal gait speed.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that occurs in 0.5% to 1% of
adults [1–3]. It causes synovial inflammation and articular erosion, and leads to progressive
functional impairment. In recent years, advancements in disease-modifying anti-rheumatoid
drugs (DMARDs) and tightly controlled treatment strategies (treat-to-target) have improved
the health status of patients with RA [4]. Nevertheless, many patients still do not achieve dis-
ease remission and suffer progressive functional impairment [5]. A recent study reported that
functional remission was not achieved in 36.6% of patients with RA 52 weeks after initiation of
treatment [6].
Walking ability is an essential part of daily living that is often impaired in patients with RA
[7]. The Health Assessment Questionnaire (HAQ) disability index, which is one of the most
commonly used tools to measure disease-specific outcomes, includes an index of walking abil-
ity [8], but it is difficult to make a detailed evaluation of the characteristics of the walking abil-
ity of patients with RA using HAQ alone. Several previous studies have analyzed the gait
parameters of patients with RA, including gait speed, step length and cadence, and have
reported that patients with RA showed lower levels of these gait parameters compared with
healthy controls [7, 9]. Some reported that gait speed showed a moderate correlation with
modified HAQ [10], and others also reported that slow gait speed was a risk factor for persis-
tent severe lower-extremity limitation, hospitalization, and mortality [11, 12]. However, there
have been no studies analyzing the factors associated with walking disability in a large cohort
of patients with RA.
In this study, we analyzed the gait parameters of patients in a single large RA cohort. The
purposes of this study were (1) to clarify the characteristics of gait parameters in patients with
RA, (2) to determine the clinical and laboratory factors associated with gait parameters in
patients with RA, and (3) to identify patients with RA who showed slow gait speed despite hav-




The study population included consecutive RA patients enrolled from the Kyoto University
Rheumatoid Arthritis Management Alliance (KURAMA) cohort from April to December
2014. The KURAMA cohort was established in 2011 at the Center for Rheumatic Diseases at
Kyoto University Hospital as a prospective diagnostic study with the aim of providing strict
control of RA, and the clinical and laboratory data of the participants have been used for previ-
ous clinical investigations [13–15]. All patients were diagnosed as RA by using the American
College of Rheumatology/European League against Rheumatism classification 1987 or 2010
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criteria for RA. During the study period from April to December 2014, a total of 396 patients
with RA were consecutively enrolled from the KURAMA cohort. Thirteen patients for whom
some data were missing were excluded from the study. In the residual 383 patients, most of the
patients were women (n = 318, 83.0%) and the number of male patients were small (n = 65,
17.0%). Therefore, the male patients were exclude from the study, and the data from 318
female patients were analyzed. This study was designed in accordance with the Helsinki decla-
ration and was approved by the ethics committee of Kyoto University Graduate School and
Faculty of Medicine. Written informed consent for this study was obtained from all participat-
ing patients.
Data collection
Clinical and laboratory data included age (years), sex, body height (cm), body weight (kg),
body mass index (kg/m2), duration of RA disease (years), Steinbrocker stage as a radiological
measure of disease stage [16], swollen and tender joint counts (SJC and TJC, respectively),
physician’s visual analog scale (dVAS), patient’s visual analog scale (pVAS), C-reactive protein
(CRP) concentration (mg/dl), the titers of rheumatoid factor (RF, U/ml) and anti-citrullinated
protein antibodies (ACPA, U/ml), HAQ score, modified Health Assessment Questionnaire
disability index (mHAQ) score, and total number of total hip, knee, and ankle arthroplasties
(THA, TKA, and TAA, respectively). Autoantibody titers were considered positive at> 15 U/
ml for RF and at> 4.5 for ACPA. HAQ and mHAQ scores are self-reported questionnaires
that assesses the physical function of patients with RA [8, 17]. Low HAQ and low mHAQ
scores represent high functional status, and an HAQ score 0.5 has been defined as one crite-
rion of minimal disease activity of RA [18, 19]. We evaluated disease activity using the Disease
Activity Score 28-CRP (DAS28-CRP) and the Clinical Disease Activity Index (CDAI). Disease
activity scores were reported to be positively correlated with HAQ [20]. The use of steroids,
methotrexate and biological DMARDs (bDMARDs) and any comorbid interstitial lung disease
were also recorded.
Knee extension strength was measured with a hand-held dynamometer (μTas F-1; ANIMA
Co., Tokyo, Japan) during isometric contraction for five seconds [21, 22]. The procedure for
measurement was kept consistent. The patients sat on the measurement table with their hip
and knee joints at angles of 90˚. The hand-held dynamometer sensor was secured to the distal
front of the lower leg with a belt, and that belt was also fixed firmly to the leg of the measure-
ment table. Measurements were taken for both legs, and the mean value of the knee extension
strength was defined as the knee extension strength of the patient.
The gait was measured with a portable triaxial accelerometer rhythmogram device (Mima-
mori-Gait1 System, LSI Medience Co., Tokyo, Japan, size 8 × 6 × 2 cm, weight 80 g). Patients
were asked to walk at their comfortable speed. The device was fixed firmly to the middle of the
patient’s lower back and three-dimensional acceleration signals were collected every 100 Hz
and automatically recorded on a secure digital memory card inserted into it for later analysis.
While the patient was walking, he or she was followed by a rehabilitation professional who
pushed the event marker button when the patient crossed the assessment start and finish lines.
The walking data was determined from these event marker recordings so that they did not
include the acceleration and deceleration walk. The number of stride events was identified
from the three-dimensional acceleration signals using an automated peak-detection algorithm,
and three basic gait parameters (step length, cadence, and gait speed) were calculated for each
patient [23, 24]. The method we used to measure the basic gait parameters with the triaxial
accelerometer was previously validated. Its inter-rater reliability and intra-rater reliability are
thought to be excellent [25]. Additionally, we measured the basic gait parameters of the three
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healthy men using our triaxial accelerometer and a tridimensional 8-camera motion capture
system (VICON1, VICON Motion System Ltd, Oxford, UK) [26], and compared the data
between them. When we measure the basic gait parameters using VICON1, spherical retro-
reflective markers were placed bilaterally following the Plug-in-Gait protocol, marker data
were sampled at 100Hz, and the basic gait parameters were calculated using Vicon polygon 4.2
software. We evaluated the agreement between these two systems using intraclass correlation
coefficient and the Pearson correlation coefficient, and found that intraclass correlation coeffi-
cient for gait speed, step length and cadence are 0.99, 0.96 and 0.99, and the Pearson correla-
tion coefficient for gait speed, step length and cadence are 0.99, 0.97 and 0.99, respectively.
Statistical analysis
The JMP Pro statistical package, version 11.0.0 (SAS Institute Inc., Cary, NC, USA) was used
for all statistical analyses, and P values less than 0.05 were considered significant. Data for con-
tinuous variables were expressed as mean and standard deviation, and data for categorical vari-
ables were expressed as numbers and percentages. For between-group comparisons, we used
the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical
variables. The Pearson correlation coefficient (r) was used to assess the relationships between
the three basic gait parameters (step length, cadence, and gait speed), the relationship between
age and these three parameters and the relationship between these three parameters and HAQ
or mHAQ. Univariate and multivariate linear regression analysis was used to identify variables
that were associated with the three gait parameters (dependent variables). We constructed
three models with forced entry for the multivariate linear regression analysis. In model 1, we
used clinical variables as the independent variables: age, body height, body weight, duration of
RA disease, Steinbrocker stage, DAS28-CRP score, steroid use, methotrexate use, bDMARDs
use, comorbid interstitial lung disease, knee extension strength, and total number of THA,
TKA, and THA. In model 2, we added the laboratory variables RF and ACPA as independent
variables. We were unable to add CRP concentration in model 2 because the DAS-28 CRP dis-
ease activity score includes the CRP concentration and was therefore collinear with CRP con-
centration. In model 3, we excluded DAS-28 CRP and replaced it with the CDAI. Because the
CDAI disease activity score does not include CRP concentration, we could also add CRP con-
centration as an independent variable in model 3. Categorical variables were coded as follows:
Steinbrocker stage: 1 (stage I), 2 (stage II), 3 (stage III), or 4 (stage IV); RF: 0 (negative) or 1
(positive); ACPA: 0 (negative) or 1 (positive); steroid use: 0 (absent) or 1 (present); methotrex-
ate use: 0 (absent) or 1 (present); bDMARDs use: 0 (absent) or 1 (present); interstitial lung dis-
ease: 0 (absent) or 1 (present). We calculated standardized partial regression coefficient (β)
and P values for the regression analysis. In addition, we divided patients with HAQ
scores 0.5 into two groups according to their gait speed, to analyze the characteristics of
patients who had a good HAQ score but poor walking ability. We defined the cut-off point for
gait speed as 1 m/s, because previous studies have reported that gait speed < 1 m/s is a risk fac-
tor for persistent severe lower-extremity limitation, hospitalization, and mortality [11, 12].
Results
Study population
A total of 318 female RA patients were analyzed. The average age at enrollment was 61.7 ± 13.4
years, and the duration of RA disease was 13.4 ± 12.5 years. Demographic data of study partici-
pants were shown in Table 1.
Walking ability in female RA patients
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Distribution of gait parameters and correlations between gait parameters
and age
The distribution of the three basic gait parameters in female RA patients is shown in Fig 1.
Their mean step length was 52.8 ± 11.9 cm, cadence 112.2 ± 13.0 steps/min, and gait speed
1.00 ± 0.28 m/s. We next evaluated the correlations between these three basic gait parameters
using the Pearson correlation coefficient. Step length was strongly correlated with gait speed
(r = 0.939, P< 0.0001), as was cadence (r = 0.666, P< 0.0001). The correlation between
cadence and step length was moderate (r = 0.401, P< 0.0001), and there were some RA
patients who had a short step length but a fast cadence, suggesting that they compensated for
their short steps with a fast cadence (Fig 2). We also evaluated the correlation between age and
these three basic gait parameters. Gait speed and step length was moderately negatively corre-
lated with age (r = -0.366, P< 0.0001 and r = 0.375, P< 0.0001, respectively). Cadence had
weak negative correlation with age (r = - 0.181, P = 0.001) (Fig 3).
Clinical and laboratory factors associated with gait parameters
We used univariate and multivariate linear regression analysis to determine which variables
were associated with the three basic gait parameters of step length, cadence, and gait speed.
Table 1. Demographic data.
Age, years 61.7 ± 13.4
Body height, cm 155.4 ± 7.1
Body weight, kg 51.1 ± 8.4
Body mass index, kg/m2 21.2 ± 3.2
Disease duration of RA, years 13.4 ± 12.5
Steinbrocker Stage, no. (%) I; 66 (20.8), II: 74 (23.3),
III; 56 (17.6), IV; 122 (38.4)
DAS28-CRP 1.94 ± 0.84
CDAI 5.92 ± 6.28
TJC, no. 0.87 ± 1.58
SJC, no 0.83 ± 0.09
dVAS 10.2 ± 11.9
pVAS 29.7 ± 24.9
CRP, mg/dl 0.34 ± 0.04
RF positive, no. (%) 233 (73.3)
ACPA positive, no. (%) 253 (79.6)
HAQ 0.77 ± 0.76
mHAQ 0.43 ± 0.03
Steroid use, no. (%) 107 (33.65)
Methotrexate use, no. (%) 216 (67.92)
Biologics use, no (%) 133 (41.82)
Interstitial pneumonia, no. (%) 50 (15.72)
Knee extension strength, N 1678.4 ± 693.3
Total number of THA, TKA and TAA, no. 0.29 ± 0.78
Data are mean ± standard deviation or n (%). DAS28-CRP, Disease Activity Score-CRP; CDAI, Clinical Disease
Activity Index; TJC, tenderness joint count; SJC, swollen joint count; dVAS, Dr’s visual analog scale; pVAS, patients’
visual analog scale; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies;
HAQ, Health Assessment Questionnaire disability index; mHAQ, modified Health Assessment Questionnaire
disability index; THA, total hip arthroplasty; TKA, total knee arthroplasty; TAA, total ankle arthroplasty.
https://doi.org/10.1371/journal.pone.0195059.t001
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We constructed three forced-entry models and calculated standardized partial regression coef-
ficient (β) and P values. In the univariate linear regression analysis, most variables were signifi-
cantly associated with one or more gait parameters (Table 2). The results of multivariate linear
regression analysis using the three models were similar (S1–S3 Tables), and are summarized in
Table 3. In all three models, knee extension strength had the strongest positive association
with the three basic gait parameters and methotrexate use was also significantly positively asso-
ciated with all three basic gait parameters. The disease activity scores (DAS-28CRP and CDAI)
and the presence of comorbid interstitial lung disease were negatively associated with step
length and gait speed in all three models. The total number of THA, TKA, and TAA was signif-
icantly negatively associated with step length in all three models, but showed no significant
association with cadence or gait speed.
Correlations between three basic gait parameters and HAQ score or
mHAQ score
We next analyzed correlation between HAQ score or mHAQ score and the three basic gait
parameters to determine whether gait parameters were correlated with the physical function of
patients with RA. Gait speed was strongly correlated with HAQ score and mHAQ score (r = –
Fig 1. Distribution of three basic gait parameters in female patients with rheumatoid arthritis. SD, standard deviation.
https://doi.org/10.1371/journal.pone.0195059.g001
Fig 2. Correlations between three basic gait parameters. Correlation plot demonstrated the very strong, strong and moderate correlations between three basic gait
parameters. r values = Pearson correlation coefficient.
https://doi.org/10.1371/journal.pone.0195059.g002
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0.591, P< 0.0001; r = –0.571, P< 0.0001, respectively), as was step length (r = –0.611,
P< 0.0001; r = –0.611, P< 0.0001, respectively). Patients with high HAQ or mHAQ scores
showed low gait speed and short step length. However, cadence was only very weakly corre-
lated with HAQ score and mHAQ score (r = –0.299, P< 0.0001; r = –0.269, P< 0.0001,
respectively), and we observed that a considerable number of patients had relatively high HAQ
or mHAQ scores but a relatively fast cadence (Fig 4).
Characteristics of patients with good HAQ scores but low gait speed
HAQ is a self-reported questionnaire that assesses the physical function of patients with RA. A
low HAQ score represents high functional status, and an HAQ score 0.5 has been defined as
Fig 3. Correlations between age and three basic gait parameters. Correlation plot demonstrated the moderate and weak correlations between age and three basic gait
parameters. r values = Pearson correlation coefficient.
https://doi.org/10.1371/journal.pone.0195059.g003
Table 2. Univariate linear regression analysis between gait parameters and clinical and laboratory variables.
Step length Cadence Gait speed
β P β P β P
Age -0.38 <0.0001 -0.18 0.0012 -0.37 <0.0001
Body height 0.35 <0.0001 0.08 0.17 0.31 <0.0001
Body weight 0.09 0.12 0.04 0.45 0.10 0.09
Duration of RA disease -0.27 <0.0001 -0.08 0.17 -0.26 <0.0001
Steinbrocker Stage -0.26 <0.0001 -0.13 0.017 -0.26 <0.0001
DAS28-CRP -0.38 <0.0001 -0.17 0.0024 -0.36 <0.0001
CDAI -0.32 <0.0001 -0.19 0.0005 -0.32 <0.0001
CRP -0.15 0.0098 -0.05 0.40 -0.14 0.016
RF positive -0.08 0.18 0.01 0.81 -0.06 0.27
ACPA positive -0.01 0.81 0.07 0.22 0.01 0.80
Steroid use -0.23 <0.0001 -0.15 0.0093 -0.23 <0.0001
Methotrexate use 0.16 0.0055 0.16 0.0058 0.18 0.0011
bDMARDs use 0.10 0.085 -0.01 0.90 0.09 0.13
Interstitial lung disease -0.32 <0.0001 -0.19 0.0008 -0.33 <0.0001
Knee extension strength 0.51 <0.0001 0.32 <0.0001 0.53 <0.0001
Total number of THA, TKA and TAA -0.31 <0.0001 -0.06 0.27 -0.27 <0.0001
β values represent standardized partial regression coefficient.
https://doi.org/10.1371/journal.pone.0195059.t002
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one criterion of minimal disease activity of RA [18, 19]. In this study, gait speed was strongly
negatively correlated with HAQ score, but there were some patients with a low (good) HAQ
score who had low gait speed (Fig 3). We divided those patients with an HAQ score 0.5 into
two groups according to their gait speed, then analyzed the characteristics of patients with
HAQ scores 0.5 but with low gait speed. Previous studies had reported that a gait speed < 1
m/s was a risk factor for persistent severe lower-extremity limitation, hospitalization and mor-
tality [11, 12], so we defined this as the cut-off point between the two groups. Of the patients
with HAQ scores 0.5, 114 (74.0%) had normal gait speed but 40 (26.0%) had low gait speed.
Table 4 shows the differences between these two groups. Patients with a good HAQ score but
low gait speed were significantly older and had significantly lower body height, longer dura-
tion of RA disease, higher disease activity score (DAS28-CRP and CDAI), higher TJC, higher
pVAS, higher CRP, higher rate of interstitial lung disease and lower knee extension strength
than patients with a good HAQ score and normal gait speed.
Discussion
In the present study, we first identified correlations between three gait parameters in the
female patients with RA. Step length was very strongly and cadence was strongly correlated
with gait speed. However, the correlation between cadence and step length was moderate,
which suggested that there were some patients who compensated for short step length by a fast
cadence. We also evaluated the correlation between age and these three basic gait parameters.
All the three gait parameters in female RA patients were negatively correlated with age, in spite
Table 3. Summary of multivariable linear regression analysis between gait parameters and clinical and laboratory
variables.
Step length Cadence Gait speed
Age (##)†
Body height ""
Body weight ## ##
Duration of RA disease
Steinbrocker Stage




Steroid use (##)† (#)†
Methotrexate use " "" ""
bDMARDs use
Interstitial lung disease ## (##)† ##
Knee extension strength """" """ """""
Total number of THA, TKA and TAA ##
", 0 < β 0.1 and P < 0.05
"", 0.1 < β 0.2 and P < 0.05
""", 0.2 < β 0.3 and P < 0.05
"""", 0.3 < β 0.4 and P < 0.05
""""", 0.4 < β 0.5 and P < 0.05
#, -0.1 < β< 0 and P < 0.05
##, -0.2 < β -0.1 and P < 0.05 in all the three models.
† represents statistically significant only in Model 3. β represents standardized partial regression coefficient.
https://doi.org/10.1371/journal.pone.0195059.t003
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of the fact that cadence in healthy people was reported not to decrease as they became older
[27]. Second, we analyzed the clinical and laboratory factors that were associated with the
three basic gait parameters. Knee extension strength had the strongest positive association
with all three basic gait parameters, and methotrexate use was also positively associated with
all three gait parameters. The disease activity scores (DAS28-CRP and CDAI) and the presence
of interstitial lung disease were negatively associated with step length and gait speed, and the
total number of THA, TKA, TAA was negatively associated only with step length. Fourth, we
showed that there were some patients who had high-risk low gait speed despite having a good
HAQ score. These patients typically were significantly older and had higher disease activity
scores (DAS28-CRP and CDAI) and significantly lower knee extension strength than patients
with a normal HAQ score and good gait speed. Even if a patient has a good HAQ score, it
would be advisable to evaluate their gait parameters if they meet these criteria. To the best of
our knowledge, this is the first study that has analyzed the characteristics of gait parameters in
a large cohort of patients with RA and the clinical and laboratory factors associated with their
walking ability.
For the female RA patients included in this study, the mean step length was 52.8 ± 11.9 cm,
mean cadence was 112.2 ± 13.0 steps/min, and mean gait speed was 1.00 ± 0.28 m/s. A previ-
ous study that analyzed the results of a 10-m walking test in 119 Japanese healthy female
Fig 4. Correlation between three basic gait parameters and HAQ score or mHAQ score. Gait speed and step length had strong correlation with HAQ score and
mHAQ score, but correlation between cadence and HAQ score or mHAQ score was very weak. r values = Pearson correlation coefficient.
https://doi.org/10.1371/journal.pone.0195059.g004
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volunteers who were 64.43 ± 10.80 years old reported that the mean step length was
67.04 ± 6.18 cm, mean cadence was 122.35 ± 7.99 steps/min, and mean gait speed was
1.37 ± 0.16 m/s [28]. Compared with these data from healthy volunteers, the step length,
cadence, and gait speed of the patients in our study were all very low, which is consistent with
the findings of previous studies [7, 9]. Furthermore, all three gait parameters in female RA
patients had negative correlation with age in this study, in spite of the fact that cadence in
healthy people was reported not to decrease as they became older [27]. These results unfortu-
nately demonstrate that even those patients who receive currently available advanced treat-
ments still show much poorer walking ability compared with the general population, and that
their walking ability gets poorer as they become older. This should be borne in mind by all
medical practitioners.
Knee extension strength provides functional stability to the knee joint. We previously
reported that knee extension strength contributed to patients’ satisfaction, symptoms, and
functional activities following TKA [29], and others have shown that quadriceps-specific exer-
cise effectively improved physical function in patients with osteoarthritis and RA [30, 31]. The
results of the multivariable regression analysis in this study clearly show that knee extension
strength have the strongest association with gait parameters in RA patients, which may prompt
Table 4. Differences between patients who had slow gait speed with HAQ score 0.5 and patients who had normal gait speed with HAQ score 0.5.
Gait speed < 1 Gait speed 1
(n = 40, 26.0%) (n = 114, 74.0%) P
Step length, cm 48.6 ± 5.7 61.3 ± 6.9 <0.0001
Cadence, steps/min 106.4 ± 8.7 118.4 ± 7.9 <0.0001
Gait speed, m/s 0.86 ± 0.12 1.21 ± 0.15 <0.0001
Age, years 62.2 ± 11.2 55.1 ± 12.9 0.0032
Body height, cm 155.5 ± 6.5 158.1 ± 6.7 0.041
Body weight, kg 53.4 ± 10.3 53.2 ± 6.8 0.06
Body mass index, kg/m2 21.2 ± 3.6 21.4 ± 3.0 0.62
Duration of RA disease, years 11.1 ± 9.3 7.9 ± 9.9 0.0093
Steinbrocker Stage, no. I; 8, II; 11, I; 44, II; 33, 0.099
III; 9, IV; 12 III; 17, IV; 20
DAS28-CRP 1.66 ± 0.63 1.42 ± 0.56 0.0069
CDAI 3.72 ± 3.34 2.55 ± 2.96 0.011
TJC, no. 0.63 ± 1.08 0.28 ± 0.68 0.047
SJC, no 0.50 ± 0.91 0.41 ± 0.92 0.35
dVAS 6.8 ± 7.9 5.1 ± 6.6 0.51
pVAS 17.2 ± 17.4 13.3 ± 16.8 0.042
CRP, mg/dl 0.34 ± 0.58 0.19 ± 0.58 0.045
RF positive, no. (%) 28 (70.0) 79 (69.3) 0.93
ACPA positive, no. (%) 27 (67.5) 92 (80.7) 0.087
Steroid use, no. (%) 13 (32.5) 27 (23.7) 0.27
Methotrexate use, no. (%) 30 (75.0) 84 (73.7) 0.87
bDMARDs use, no (%) 15 (37.5) 51 (44.7) 0.43
Interstitial lung disease, no. (%) 7 (17.5) 6 (5.3) 0.017
Knee extension strength, N 1478.1 ± 519.5 2109.9 ± 636.0 <0.0001
Total number of THA, TKA and TAA, no. 0.05 ± 0.22 0.06 ± 0.31 0.90
Data are mean ± standard deviation or n (%). P value were derived from Wilcoxon rank-sum test or chi-square test.
https://doi.org/10.1371/journal.pone.0195059.t004
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physicians and societies to plan a rehabilitation program or daily exercise program to improve
knee extension strength in RA patients.
DAS-28-CRP and CDAI are objective and standardized tools to evaluate disease activity
and the response to treatment in patients with RA [32, 33]. These disease activity indices have
been reported previously to be good indicators of functional capacity in patients with RA [20,
34]. In this study, DAS28-CRP and CDAI scores were negatively associated with step length
and gait speed. Therefore, this study may also support the prevailing concept that maintaining
low disease activity is crucial to sustaining good functional ability in RA patients, although this
study particularly emphasized the maintenance of their walking ability.
Surprisingly, this study also showed methotrexate use was significantly positively associated
with all three basic gait parameters, independent of disease activity. To clarify the reasons for
this result, we evaluated the differences between patients treated and not treated with metho-
trexate (S4 Table). The DAS28-CRP and CDAI disease activity scores were similar in the two
groups, but pVAS was significantly lower in patients treated with methotrexate than those
without methotrexate. This result may suggest the possibility that methotrexate benefits
patients by reducing their pain, which could contribute to maintaining their walking ability.
Indeed, previous studies reported that methotrexate reduced pain not only in patients with RA
but also in patients with osteoarthritis [35, 36]. However, there were difference in age between
these two groups, and this study is just a cross-sectional study. This hypothesis requires testing
in a longitudinal prospective study.
This study also clearly demonstrated that a part of patients with RA report good functional
ability in terms of a low HAQ score but have poor walking ability. This subset of patients
requires careful attention from physicians and societies. The risk factors of these patients are
similar to the general risk factors associated with poorer walking ability, such as weaker knee
extension strength and higher disease activity, but also suggest that older patients with longer
duration of RA disease, higher pVAS, higher CRP, more TJC, and with interstitial lung disease
should be monitored carefully in terms of their walking ability. These results are also consis-
tent with those of a previous study that reported that patients with interstitial pneumonia
exhibited reduced levels of physical activity in daily life and a 65% decrease in the number of
steps taken per day compared with the sedentary healthy control population [37].
This study has several limitations. First, because this study was cross-sectional, it is possible
that a longitudinal study would identify additional variables associated with gait parameters,
and we couldn’t determine the causal relation between walking ability and the other variables.
Second, we analyzed only the women because the majority of our study participants were
women. Analyses of male patients might show different results. Third, we measured the knee
extension strength using the hand-held dynamometer with a restraining belt. This method was
previously validated, and its interrater reliability was regarded as excellent (interclass correla-
tion coefficient: 0.98) [38]. However, the validity of this method has not been compared with
the Biodex system (Biodex Medical Systems Inc., NY, USA) which is the gold standard for iso-
metric strength testing [39]. Lastly, we hypothesized that the presence of comorbid interstitial
lung disease affected the walking ability of patients with RA, which was partly validated. How-
ever, other comorbidities such as heart diseases could also affect walking ability. These factors
should be investigated in future studies.
In conclusion, we analyzed the gait parameters of a cohort of patients with RA and the fac-
tors associated with those gait parameters. Knee extension strength showed the strongest posi-
tive association with three basic gait parameters, while methotrexate use was also positively
associated with these three parameters. The DAS-28-CRP and CDAI disease activity scores
were negatively associated with step length and gait speed. In addition, patients who reported
good functional ability in terms of low HAQ scores but had poor walking ability had
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significantly higher disease activity scores and lower knee extension strength compared with
patients who reported good functional ability and had normal walking ability. These results
may suggest that it is important for walking ability in RA patients that they maintain good
knee extension strength and low disease RA activity with methotrexate treatment. A further
longitudinal prospective study is required.
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